Curia New York
United States Updated 9 July 2026
Curia New York is an API manufacturer based in United States. It holds 17 active US drug master files across a filed portfolio of 13 molecules. Its most recent recorded inspection, by US FDA, closed on 5 February 2026 as OAI.
1
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 5 February 2026 OAI US FDA
- 1 November 2023 VAI US FDA
- 9 November 2017 VAI US FDA
- 22 May 2015 VAI US FDA
- 15 January 2014 VAI US FDA
- 30 January 2013 VAI US FDA
- 29 March 2012 NAI US FDA
- 7 April 2010 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Rensselaer, United States | 1310298 |
What they file, and where
| Molecule | Regulators | Docs |
| Amphetamine | US FDA | 3 |
| Dextroamphetamine | US FDA | 3 |
| Cannabidiol | US FDA | 1 |
| Echothiophate | US FDA | 1 |
| Epinephrine | US FDA | 1 |
| Meperidine | US FDA | 1 |
| Metolazone | US FDA | 1 |
| Norepinephrine | US FDA | 1 |
| Pentobarbital | US FDA | 1 |
| Pralidoxime | US FDA | 1 |
Show all 13 molecules on file
| Racepinephrine | US FDA | 1 |
| Triethylenetetramine | US FDA | 1 |
| Vorinostat | US FDA | 1 |
Also appears on these molecule pages
Comparing suppliers?
Choose your molecules and target markets. Curia New York comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- 3 active litigation matters are on record.
- The most recent inspection outcome was OAI, on 5 February 2026.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability